Viva Biotech Holdings (VB0) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Viva Biotech Holdings (VB0) has a cash flow conversion efficiency ratio of 0.044x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€158.72 Million ≈ $185.57 Million USD) by net assets (€3.64 Billion ≈ $4.26 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see VB0 market cap overview for the company's overall valuation and market capitalisation.
Viva Biotech Holdings - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Viva Biotech Holdings's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Viva Biotech Holdings Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Viva Biotech Holdings ranked by their cash flow conversion efficiency. Explore Viva Biotech Holdings cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lumax International Corp Ltd
TW:6192
|
0.027x |
|
Hainan Huluwa Pharmaceutical Group Co Ltd
SHG:605199
|
0.103x |
|
Aramis SAS
PA:ARAMI
|
0.246x |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
0.013x |
|
Transcontinental Realty Investors
NYSE:TCI
|
-0.003x |
|
Suzhou Jin Hong Shun Auto Parts Co Ltd Class A
SHG:603922
|
-0.006x |
|
Good Will Instrument Co Ltd
TW:2423
|
-0.008x |
|
YUEXIU SERVICES GROUP LTD
F:5R9
|
N/A |
Annual Cash Flow Conversion Efficiency for Viva Biotech Holdings (2016–2024)
The table below shows the annual cash flow conversion efficiency of Viva Biotech Holdings from 2016 to 2024. View latest Viva Biotech Holdings stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €3.82 Billion ≈ $4.46 Billion |
€373.99 Million ≈ $437.23 Million |
0.098x | -5.74% |
| 2023-12-31 | €3.69 Billion ≈ $4.31 Billion |
€383.40 Million ≈ $448.24 Million |
0.104x | -2.93% |
| 2022-12-31 | €3.60 Billion ≈ $4.21 Billion |
€386.05 Million ≈ $451.33 Million |
0.107x | +438.49% |
| 2021-12-31 | €3.91 Billion ≈ $4.58 Billion |
€77.83 Million ≈ $90.99 Million |
0.020x | +73.03% |
| 2020-12-31 | €3.76 Billion ≈ $4.39 Billion |
€43.18 Million ≈ $50.48 Million |
0.011x | -55.60% |
| 2019-12-31 | €1.78 Billion ≈ $2.08 Billion |
€46.01 Million ≈ $53.79 Million |
0.026x | -46.25% |
| 2018-12-31 | €251.44 Million ≈ $293.96 Million |
€12.11 Million ≈ $14.16 Million |
0.048x | -73.62% |
| 2017-12-31 | €152.76 Million ≈ $178.59 Million |
€27.89 Million ≈ $32.61 Million |
0.183x | -33.86% |
| 2016-12-31 | €76.50 Million ≈ $89.44 Million |
€21.12 Million ≈ $24.69 Million |
0.276x | -- |
About Viva Biotech Holdings
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such a… Read more